Subtype
Lung Carcinoma
CI-CAN-00001086Explore in graph →
2,130 active trials51 approved drugs598 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001086Explore in graph →
Clinical trials
7,792 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,179)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03848611 | CM082 and JS001 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC). | unknown | Phase 2 | 20 | AnewPharmaINDUSTRY | 1 | Jul 9, 2020 | clinicaltrials |
| NCT03904719 | CM082 and JS001 in Patients With Advanced Small-cell Lung Cancer (SCLC) | unknown | Phase 2 | 30 | AnewPharmaINDUSTRY | 1 | Jul 9, 2020 | clinicaltrials |
| NCT04273815 |
| A Study to Evaluate the Tolerance, Pharmacokinetics and Efficacy of TQ-A3334 Tablets |
| unknown |
| Phase 1 / Phase 2 |
| 40 |
| Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY |
| 1 |
| Jul 8, 2020 |
| clinicaltrials |
| NCT01746251 | Adjuvant Afatinib in Stage I-III NSCLC With EGFR Mutation | unknown | Phase 2 | 92 | Massachusetts General HospitalOTHER | 1 | Jul 7, 2020 | clinicaltrials |
| NCT04459663 | JS001 Combination Therapy in NSCLC Negative Driving Gene After First-line Chemotherapy. | unknown | Phase 2 | 50 | Li Zhang, MDOTHER | 1 | Jul 7, 2020 | clinicaltrials |
| NCT04455594 | Almonertinib Vs. Erlotinib/Chemotherapy for Neo-adjuVant Treatment of Stage IIIA-N2 EGFR-mutated NSCLC(ANSWER) | unknown | Phase 2 | 168 | The First Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jul 2, 2020 | clinicaltrials |
| NCT02737774 | Alternating Icotinib and Chemotherapy for Advanced Non-small Cell Lung Cancer With EGFR Mutation | unknown | Phase 2 | 60 | Henan Cancer HospitalOTHER_GOV | 1 | Jul 1, 2020 | clinicaltrials |
| NCT04453423 | Combination Chemotherapy With or Without Anlotinib in the Maintenance Treatment of Non-Squamous Non-Small Cell Lung Cancer. | unknown | Phase 2 | 90 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 0 | Jul 1, 2020 | clinicaltrials |
| NCT04453930 | A Study of Sequential Therapy of Camrelizumab Combined With Chemotherapy（Irinotecan Plus Platinum）and With Apatinib in Participants With Untreated Advanced Small Cell Lung Cancer（SCLC） | unknown | Phase 2 | 60 | Peking Union Medical College HospitalOTHER | 1 | Jul 1, 2020 | clinicaltrials |
| NCT03571360 | CTA Expression/Methylation and Response to Pembrolizumab of NSCLC Patients | unknown | Phase 2 | 42 | Medical University of ViennaOTHER | 1 | Jun 11, 2020 | clinicaltrials |
| NCT03983759 | Study of Sintlimab Maintenance Therapy in Patients With Extensive Small Cell Lung Cancer | unknown | Phase 2 | 40 | Henan Cancer HospitalOTHER_GOV | 1 | Jun 11, 2020 | clinicaltrials |
| NCT04425681 | Osimertinib With Bevacizumab for Leptomeningeal Metastasis From EGFR-mutation Non-Small Cell Lung Cancer(OWBLM) | unknown | Phase 2 | 20 | Second Affiliated Hospital of Nanchang UniversityOTHER | 1 | Jun 11, 2020 | clinicaltrials |
| NCT04371796 | Sintilimab (IBI308) in the Neoadjuvant Treatment of Patients With Resectable II-IIIA NSCLC | unknown | Phase 2 | 20 | Sichuan Cancer Hospital and Research InstituteOTHER | 0 | May 1, 2020 | clinicaltrials |
| NCT04363255 | First-line Chemotherapy Followed by Toripalimab Combined With Anlotinib for Maintenance in ES-SCLC | unknown | Phase 2 | 20 | Taizhou HospitalOTHER | 1 | Apr 28, 2020 | clinicaltrials |
| NCT04358562 | Gefitinib With Anlotinib in Advanced Non-squamous NSCLC Patients With Uncleared Plasma ctDNA EGFRm After First-line Treatment With Gefitinib | unknown | Phase 2 | 240 | Second Affiliated Hospital of Nanchang UniversityOTHER | 1 | Apr 24, 2020 | clinicaltrials |
| NCT04339829 | An Open Label, Multicenter, Phase II Study of Dacomitinib for EGFR Mutated Non-Small Cell Lung Cancer (NSCLC) With Brain Metastases | unknown | Phase 2 | 50 | Guangdong Association of Clinical TrialsOTHER | 0 | Apr 9, 2020 | clinicaltrials |
| NCT03706287 | Efficacy and Safety of Anlotinib Plus Platinum Plus Pemetrexed in T790M-negative NSCLC | unknown | Phase 1 / Phase 2 | 62 | Sichuan Cancer Hospital and Research InstituteOTHER | 1 | Apr 6, 2020 | clinicaltrials |
| NCT04333004 | Analysis of Gut Microbiota in Patients With Brain Metastasis of Non-small Cell Lung Cancer Treated by Pembrolizumab Combined With Chemotherapy | unknown | Phase 1 / Phase 2 | 40 | Xiaorong DongOTHER | 0 | Apr 3, 2020 | clinicaltrials |
| NCT03823625 | An Open-label, Randomized, Parallel, Non Comparative, Phase II Trial of Nivolumab Plus Ipilimumab Versus Platinum-based Chemotherapy Plus Nivolumab in Chemonaive Metastatic or Recurrent Squamous-Cell Lung Cancer (SqLC)(SQUINT) | unknown | Phase 2 | 112 | Fondazione Ricerca TraslazionaleOTHER | 1 | Mar 25, 2020 | clinicaltrials |
| NCT04314297 | Anlotinib In Combination With Durvalumab As Sequential Therapy of Thoracic Radiotherapy After Induction Chemotherapy For Extensive-Stage Small Cell Lung Cancer:A Single Arm Study | unknown | Phase 2 | 33 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 0 | Mar 19, 2020 | clinicaltrials |
| NCT03119519 | Local Non-salvage Radiotherapy for Synchronous Oligometastatic Non-small-cell Lung Cancer. | unknown | Phase 2 | 148 | Southern Medical University, ChinaOTHER | 1 | Mar 18, 2020 | clinicaltrials |
| NCT04303130 | Camrelizumab Combined With Endostar for First-line Treatment in Subjects With Advanced Squamous NSCLC | unknown | Phase 2 | 52 | Peking University Cancer Hospital & InstituteOTHER | 1 | Mar 10, 2020 | clinicaltrials |
| NCT03585998 | Chemoradiation With Durvalumab Followed by Durvalumab Maintenance for Limited Disease Small Cell Lung Cancer | unknown | Phase 2 | 51 | Samsung Medical CenterOTHER | 1 | Mar 2, 2020 | clinicaltrials |
| NCT02583542 | A Study of AZD2014 in Combination With Selumetinib in Patients With Advanced Cancers(TORCMEK) | unknown | Phase 1 / Phase 2 | 118 | Queen Mary University of LondonOTHER | 1 | Feb 25, 2020 | clinicaltrials |
| NCT04284202 | PD-1 Combined With Dasatinib for as Third-line Treatment for ARID1A Mutation Advanced NSCLC | unknown | Phase 2 | 30 | The Affiliated Hospital of Qingdao UniversityOTHER | 1 | Feb 25, 2020 | clinicaltrials |
| NCT02725918 | Pemetrexed vs Pemetrexed Plus Cisplatin in EGFR-mutant NSCLC Patients After First Line EGFR-TKIs Failure | unknown | Phase 2 | 150 | Guangdong Association of Clinical TrialsOTHER | 1 | Feb 12, 2020 | clinicaltrials |
| NCT03557411 | A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Hypofraction Radiotherapy in Patients With NSCLC | unknown | Phase 2 | 42 | Shandong Cancer Hospital and InstituteOTHER | 1 | Feb 5, 2020 | clinicaltrials |
| NCT03613597 | Etoposide Plus Lobaplatin Versus Etoposide Plus Cisplatin for Patients With Limited Small-cell Lung Cancer | unknown | Phase 2 | 118 | Guizhou Medical UniversityOTHER | 1 | Feb 5, 2020 | clinicaltrials |
| NCT03613753 | Irinotecan Plus Lobaplatin Versus Irinotecan in the Second-line Treatment of Small Cell Lung Cancer | unknown | Phase 2 | 72 | ShengFa SuOTHER | 1 | Feb 5, 2020 | clinicaltrials |
| NCT04252365 | Sintilimab Versus Pembrolizumab for Advanced-stage Non-Small-Cell Lung Cancer | unknown | Phase 2 | 20 | Guangdong Association of Clinical TrialsOTHER | 0 | Feb 5, 2020 | clinicaltrials |
| NCT04254471 | This Phase II/III, Multicenter Study is Designed to Evaluate the Safety and Clinical Activity of AL3810 in Patients | unknown | Phase 2 / Phase 3 | 313 | Haihe Biopharma Co., Ltd.INDUSTRY | 1 | Feb 5, 2020 | clinicaltrials |
| NCT04255836 | Durvalumab Combined With Chemotherapy and Stereotactic Body Radiotherapy (SBRT) in Patients With Oligometastatic Non-small Cell Lung Cancer (NSCLC) | unknown | Phase 2 | 35 | Zhejiang Cancer HospitalOTHER | 0 | Feb 5, 2020 | clinicaltrials |
| NCT01795521 | LungTech: Stereotactic Body Radiotherapy (SBRT) of Inoperable Centrally Located NSCLC(LungTech) | unknown | Phase 2 | 39 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 4 | Jan 31, 2020 | clinicaltrials |
| NCT04250246 | A Study of NIVO Plus IPI and Guadecitabine or NIVO Plus IPI in Melanoma and NSCLC Resistant to Anti-PD1/PDL1(NIBIT-ML1) | unknown | Phase 2 | 184 | Italian Network for Tumor Biotherapy FoundationOTHER | 1 | Jan 31, 2020 | clinicaltrials |
| NCT02416739 | Anticancer Activity of Nicotinamide on Lung Cancer | unknown | Phase 2 / Phase 3 | 110 | Il Yeong Park, Ph.D.OTHER | 1 | Jan 27, 2020 | clinicaltrials |
| NCT04239443 | Clinical Study of PD-1 Monoclonal Antibody SHR-1210 and Apatinib in Advanced NSCLC, Soft Tissue Sarcoma, and Uterine Cancer | unknown | Phase 2 | 120 | Hunan Cancer HospitalOTHER | 1 | Jan 27, 2020 | clinicaltrials |
| NCT03624309 | Anlotinib Plus Docetaxel for the Treatment of EGFR Wild-type Advanced Non-small-cell Lung Cancer | unknown | Phase 2 | 84 | Hunan Cancer HospitalOTHER | 1 | Jan 7, 2020 | clinicaltrials |
| NCT04192682 | Anlotinib Combined With Sintilimab as Second-line Treatment or Beyond in Patients With Small Cell Lung Cancer | unknown | Phase 2 / Phase 3 | 40 | Changzhou Cancer Hospital of Soochow UniversityOTHER | 1 | Jan 6, 2020 | clinicaltrials |
| NCT04213170 | Sintilimab Combined With Bevacizumab for Brain Metastases From Non-small Cell Lung Cancer | unknown | Phase 2 | 60 | Sun Yat-sen UniversityOTHER | 1 | Dec 30, 2019 | clinicaltrials |
| NCT04213937 | Nab-paclitaxel Versus Topotecan As Second-Line Treatment for Patients With Extensive Stage Small Cell Lung Cancer | unknown | Phase 2 | 386 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Dec 30, 2019 | clinicaltrials |
| NCT04211896 | Anlotinib Combined With Nivolumab for Non-Small Cell Lung Cancer | unknown | Phase 2 | 70 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 0 | Dec 26, 2019 | clinicaltrials |
| NCT04199559 | Evaluating Combination Therapy Using Autologous Dendritic Cells Pulsed With Antigen Peptides and Nivolumab for Subjects With Advanced Non-Small Cell Lung Cancer | unknown | Phase 1 / Phase 2 | 30 | Henan Cancer HospitalOTHER_GOV | 1 | Dec 16, 2019 | clinicaltrials |
| NCT04193007 | The Role of Brain Radiotherapy in Patients With Asymptomatic Brain Metastasis in the Era of Targeted Therapy for NSCLC(BRATR) | unknown | Phase 2 | 100 | Second Affiliated Hospital of Nanchang UniversityOTHER | 1 | Dec 10, 2019 | clinicaltrials |
| NCT04182698 | Study of Anlotinib Plus Chemoradiotherapy in Patients With Locally Advanced NSCLC | unknown | Phase 1 / Phase 2 | 90 | Second Affiliated Hospital of Xi'an Jiaotong UniversityOTHER | 1 | Dec 2, 2019 | clinicaltrials |
| NCT03700359 | A Study of Lobaplatin/Etoposide With or Without Anlotinib Maintenance Therapy in Patients With ES-SCLC | unknown | Phase 2 | 60 | The First Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Nov 29, 2019 | clinicaltrials |
| NCT04181372 | A Study of Neoadjuvant Chemotherapy Plus Anlotinib in Stage III(N2) Non-small-cell Lung Cancer | unknown | Phase 2 | 50 | The First Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Nov 29, 2019 | clinicaltrials |
| NCT04180501 | SRS Sequential Sindilimab in Brain Metastasis of NSLSC | unknown | Phase 2 | 25 | Xiaorong DongOTHER | 1 | Nov 27, 2019 | clinicaltrials |
| NCT04167774 | A Study to Evaluate Camrelizumab in Combination With Nb-Paclitaxel in Patients With Advanced or Metastatic NSCLC(Compass-001) | unknown | Phase 2 | 62 | Sun Yat-sen UniversityOTHER | 1 | Nov 22, 2019 | clinicaltrials |
| NCT04164745 | Efficacy and Safety Study of Anlotinib With Pembrolizumab in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Non-small Cell Lung Cancer | unknown | Phase 2 | 49 | Peking Union Medical College HospitalOTHER | 1 | Nov 15, 2019 | clinicaltrials |
| NCT02367443 | Hypofractionated Accelerated Radiotherapy With Concomitant Chemotherapy for NSCLC | unknown | Phase 1 / Phase 2 | 92 | Independent Public Care Health Facility of the Ministry of the Interior and Warmian & Mazurian Oncology CentreOTHER | 1 | Nov 6, 2019 | clinicaltrials |
Data updated 23 days agoSource updated Jul 9, 2020source: clinicaltrials